Leukemia/Lymphoma
RSSArticles
-
More on Vitamin E and Prostate Cancer
-
Lessons in Supportive Care, IX: Do Medical Care Interventions Ever Save Money?
-
Cancer Screening's Next Chapter: Mobile CT Scanning for Lung Cancer
-
Systemic Radiation Therapy Using Receptor Specific Radioligands: Experience with
-
Concomitant and Subsequent Chemotherapy Enhances Responses to Advanced Nasophary
-
Lowering the Threshold for Prophylactic Platelet Transfusion: Is the Risk of
-
Cancer-reducing Effect of OCPs in BRCA1/BRCA2 Carriers: Do They Work?
The association between oral contraceptive use and ovarian or breast cancer in BRCA1 or BRCA2 mutation carriers are qualitatively similar to associations reported in the general population. -
Toward More Effective Neoadjuvant Breast Cancer Therapy
In a Phase 3, randomized clinical trial of primary systemic therapy for patients with early, locally advanced breast cancer, the addition of capecitabine to each of six 3-weekly cycles of epirubicin-docetaxel resulted in a 1.64 fold increase in the possibility of primary tumor pathologic complete response. -
Bendamustine-Bortezomib-Dexamethasone for Relapsed Myeloma
In a Phase 2 trial, Ludwig and colleagues present data on 79 patients with relapsed or refractory myeloma who were treated with bendamustine in combination with bortezomib and dexamethasone. -
Second-line Docetaxel Improves Survival and Symptom Control in Advanced Esophagogastric Cancer
Patients with progressive advanced esophagogastric adenocarcinoma treated with docetaxel in addition to active symptom control (ASC) survived 44% longer than those who received ASC alone.